Selected research
Industry Research
Anti-Beta-Actin Antibody Industry Research Report 2026
Market perspective
The global Anti-Beta-Actin Antibody market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
The North America market for Anti-Beta-Actin Antibody is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026–2032.
The Europe market for Anti-Beta-Actin Antibody is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032.
Read the full market overview
The Asia Pacific market for Anti-Beta-Actin Antibody is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032.
Leading global manufacturers of Anti-Beta-Actin Antibody include NCM Biotech, BioPioneer Tech, YaJi Biological, Thermo Fisher Scientific, Merck, Genscript, Santa Cruz Biotechnology, Proteintech and Novus Biologicals, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
This report quantifies the global Anti-Beta-Actin Antibody market in terms of revenue (US$ million) and, where applicable, sales volume (ml), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/ml) and concentration ratios (CR5/CR10).
The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.
Key Companies & Market Share Insights
This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Anti-Beta-Actin Antibody Market by Company
NCM Biotech
BioPioneer Tech
YaJi Biological
Thermo Fisher Scientific
Merck
Genscript
Santa Cruz Biotechnology
Proteintech
Novus Biologicals
GeneTex
Cell Signaling Technology (CST)
Biosharp
BioLegend
BD Biosciences
Abcam
Anti-Beta-Actin Antibody Segment by Type
Monoclonal
Polyclonal
Anti-Beta-Actin Antibody Segment by Application
Immunohistochemistry (IHC)
Immunocytochemistry (ICC)
Others
Anti-Beta-Actin Antibody Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Anti-Beta-Actin Antibody market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Anti-Beta-Actin Antibody and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Anti-Beta-Actin Antibody.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Detailed analysis of Anti-Beta-Actin Antibody manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.
Chapter 5: Production/output, value of Anti-Beta-Actin Antibody by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.
Chapter 6: Consumption of Anti-Beta-Actin Antibody in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.
Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 11: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Monoclonal
- Polyclonal
Applications
- Immunohistochemistry (IHC)
- Immunocytochemistry (ICC)
- Others
Companies covered
- NCM Biotech
- BioPioneer Tech
- YaJi Biological
- Thermo Fisher Scientific
- Merck
- Genscript
- Santa Cruz Biotechnology
- Proteintech
- Novus Biologicals
- GeneTex
- Cell Signaling Technology (CST)
- Biosharp
- BioLegend
- BD Biosciences
- Abcam
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Global Market Growth Prospects
- 2.2.1 Global Anti-Beta-Actin Antibody Market Size (2021-2032)
- 2.2.2 Global Anti-Beta-Actin Antibody Sales (2021-2032)
- 2.2.3 Global Anti-Beta-Actin Antibody Market Average Price (2021-2032)
- 2.3 Anti-Beta-Actin Antibody by Type
- 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
- 2.3.2 Monoclonal
- 2.3.3 Polyclonal
- 2.4 Anti-Beta-Actin Antibody by Application
- 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.4.2 Immunohistochemistry (IHC)
- 2.4.3 Immunocytochemistry (ICC)
- 2.4.4 Others
3 Market Competitive Landscape by Manufacturers
- 3.1 Global Anti-Beta-Actin Antibody Market Competitive Situation by Manufacturers (2021 Versus 2025)
- 3.2 Global Anti-Beta-Actin Antibody Sales (ml) of Manufacturers (2021-2026)
- 3.3 Global Anti-Beta-Actin Antibody Revenue of Manufacturers (2021-2026)
- 3.4 Global Anti-Beta-Actin Antibody Average Price by Manufacturers (2021-2026)
- 3.5 Global Anti-Beta-Actin Antibody Industry Ranking, 2024 VS 2025 VS 2026
- 3.6 Global Manufacturers of Anti-Beta-Actin Antibody, Manufacturing Sites & Headquarters
- 3.7 Global Manufacturers of Anti-Beta-Actin Antibody, Product Type & Application
- 3.8 Global Manufacturers of Anti-Beta-Actin Antibody, Established Date
- 3.9 Global Anti-Beta-Actin Antibody Market CR5 and HHI
- 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
- 4.1 NCM Biotech
- 4.1.1 NCM Biotech Company Information
- 4.1.2 NCM Biotech Business Overview
- 4.1.3 NCM Biotech Anti-Beta-Actin Antibody Sales, Revenue and Gross Margin (2021-2026)
- 4.1.4 NCM Biotech Anti-Beta-Actin Antibody Product Portfolio
- 4.1.5 NCM Biotech Recent Developments
- 4.2 BioPioneer Tech
- 4.2.1 BioPioneer Tech Company Information
- 4.2.2 BioPioneer Tech Business Overview
- 4.2.3 BioPioneer Tech Anti-Beta-Actin Antibody Sales, Revenue and Gross Margin (2021-2026)
- 4.2.4 BioPioneer Tech Anti-Beta-Actin Antibody Product Portfolio
- 4.2.5 BioPioneer Tech Recent Developments
- 4.3 YaJi Biological
- 4.3.1 YaJi Biological Company Information
- 4.3.2 YaJi Biological Business Overview
- 4.3.3 YaJi Biological Anti-Beta-Actin Antibody Sales, Revenue and Gross Margin (2021-2026)
- 4.3.4 YaJi Biological Anti-Beta-Actin Antibody Product Portfolio
- 4.3.5 YaJi Biological Recent Developments
- 4.4 Thermo Fisher Scientific
- 4.4.1 Thermo Fisher Scientific Company Information
- 4.4.2 Thermo Fisher Scientific Business Overview
- 4.4.3 Thermo Fisher Scientific Anti-Beta-Actin Antibody Sales, Revenue and Gross Margin (2021-2026)
- 4.4.4 Thermo Fisher Scientific Anti-Beta-Actin Antibody Product Portfolio
- 4.4.5 Thermo Fisher Scientific Recent Developments
- 4.5 Merck
- 4.5.1 Merck Company Information
- 4.5.2 Merck Business Overview
- 4.5.3 Merck Anti-Beta-Actin Antibody Sales, Revenue and Gross Margin (2021-2026)
- 4.5.4 Merck Anti-Beta-Actin Antibody Product Portfolio
- 4.5.5 Merck Recent Developments
- 4.6 Genscript
- 4.6.1 Genscript Company Information
- 4.6.2 Genscript Business Overview
- 4.6.3 Genscript Anti-Beta-Actin Antibody Sales, Revenue and Gross Margin (2021-2026)
- 4.6.4 Genscript Anti-Beta-Actin Antibody Product Portfolio
- 4.6.5 Genscript Recent Developments
- 4.7 Santa Cruz Biotechnology
- 4.7.1 Santa Cruz Biotechnology Company Information
- 4.7.2 Santa Cruz Biotechnology Business Overview
- 4.7.3 Santa Cruz Biotechnology Anti-Beta-Actin Antibody Sales, Revenue and Gross Margin (2021-2026)
- 4.7.4 Santa Cruz Biotechnology Anti-Beta-Actin Antibody Product Portfolio
- 4.7.5 Santa Cruz Biotechnology Recent Developments
- 4.8 Proteintech
- 4.8.1 Proteintech Company Information
- 4.8.2 Proteintech Business Overview
- 4.8.3 Proteintech Anti-Beta-Actin Antibody Sales, Revenue and Gross Margin (2021-2026)
- 4.8.4 Proteintech Anti-Beta-Actin Antibody Product Portfolio
- 4.8.5 Proteintech Recent Developments
- 4.9 Novus Biologicals
- 4.9.1 Novus Biologicals Company Information
- 4.9.2 Novus Biologicals Business Overview
- 4.9.3 Novus Biologicals Anti-Beta-Actin Antibody Sales, Revenue and Gross Margin (2021-2026)
- 4.9.4 Novus Biologicals Anti-Beta-Actin Antibody Product Portfolio
- 4.9.5 Novus Biologicals Recent Developments
- 4.10 GeneTex
- 4.10.1 GeneTex Company Information
- 4.10.2 GeneTex Business Overview
- 4.10.3 GeneTex Anti-Beta-Actin Antibody Sales, Revenue and Gross Margin (2021-2026)
- 4.10.4 GeneTex Anti-Beta-Actin Antibody Product Portfolio
- 4.10.5 GeneTex Recent Developments
- 4.11 Cell Signaling Technology (CST)
- 4.11.1 Cell Signaling Technology (CST) Company Information
- 4.11.2 Cell Signaling Technology (CST) Business Overview
- 4.11.3 Cell Signaling Technology (CST) Anti-Beta-Actin Antibody Sales, Revenue and Gross Margin (2021-2026)
- 4.11.4 Cell Signaling Technology (CST) Anti-Beta-Actin Antibody Product Portfolio
- 4.11.5 Cell Signaling Technology (CST) Recent Developments
- 4.12 Biosharp
- 4.12.1 Biosharp Company Information
- 4.12.2 Biosharp Business Overview
- 4.12.3 Biosharp Anti-Beta-Actin Antibody Sales, Revenue and Gross Margin (2021-2026)
- 4.12.4 Biosharp Anti-Beta-Actin Antibody Product Portfolio
- 4.12.5 Biosharp Recent Developments
- 4.13 BioLegend
- 4.13.1 BioLegend Company Information
- 4.13.2 BioLegend Business Overview
- 4.13.3 BioLegend Anti-Beta-Actin Antibody Sales, Revenue and Gross Margin (2021-2026)
- 4.13.4 BioLegend Anti-Beta-Actin Antibody Product Portfolio
- 4.13.5 BioLegend Recent Developments
- 4.14 BD Biosciences
- 4.14.1 BD Biosciences Company Information
- 4.14.2 BD Biosciences Business Overview
- 4.14.3 BD Biosciences Anti-Beta-Actin Antibody Sales, Revenue and Gross Margin (2021-2026)
- 4.14.4 BD Biosciences Anti-Beta-Actin Antibody Product Portfolio
- 4.14.5 BD Biosciences Recent Developments
- 4.15 Abcam
- 4.15.1 Abcam Company Information
- 4.15.2 Abcam Business Overview
- 4.15.3 Abcam Anti-Beta-Actin Antibody Sales, Revenue and Gross Margin (2021-2026)
- 4.15.4 Abcam Anti-Beta-Actin Antibody Product Portfolio
- 4.15.5 Abcam Recent Developments
5 Global Anti-Beta-Actin Antibody Market Scenario by Region
- 5.1 Global Anti-Beta-Actin Antibody Market Size by Region: 2021 VS 2025 VS 2032
- 5.2 Global Anti-Beta-Actin Antibody Sales by Region: 2021-2032
- 5.2.1 Global Anti-Beta-Actin Antibody Sales by Region: 2021-2026
- 5.2.2 Global Anti-Beta-Actin Antibody Sales by Region: 2027-2032
- 5.3 Global Anti-Beta-Actin Antibody Revenue by Region: 2021-2032
- 5.3.1 Global Anti-Beta-Actin Antibody Revenue by Region: 2021-2026
- 5.3.2 Global Anti-Beta-Actin Antibody Revenue by Region: 2027-2032
- 5.4 North America Anti-Beta-Actin Antibody Market Facts & Figures by Country
- 5.4.1 North America Anti-Beta-Actin Antibody Market Size by Country: 2021 VS 2025 VS 2032
- 5.4.2 North America Anti-Beta-Actin Antibody Sales by Country (2021-2032)
- 5.4.3 North America Anti-Beta-Actin Antibody Revenue by Country (2021-2032)
- 5.4.4 United States
- 5.4.5 Canada
- 5.4.6 Mexico
- 5.5 Europe Anti-Beta-Actin Antibody Market Facts & Figures by Country
- 5.5.1 Europe Anti-Beta-Actin Antibody Market Size by Country: 2021 VS 2025 VS 2032
- 5.5.2 Europe Anti-Beta-Actin Antibody Sales by Country (2021-2032)
- 5.5.3 Europe Anti-Beta-Actin Antibody Revenue by Country (2021-2032)
- 5.5.4 Germany
- 5.5.5 France
- 5.5.6 U.K.
- 5.5.7 Italy
- 5.5.8 Russia
- 5.5.9 Spain
- 5.5.10 Netherlands
- 5.5.11 Switzerland
- 5.5.12 Sweden
- 5.5.13 Poland
- 5.6 Asia Pacific Anti-Beta-Actin Antibody Market Facts & Figures by Country
- 5.6.1 Asia Pacific Anti-Beta-Actin Antibody Market Size by Country: 2021 VS 2025 VS 2032
- 5.6.2 Asia Pacific Anti-Beta-Actin Antibody Sales by Country (2021-2032)
- 5.6.3 Asia Pacific Anti-Beta-Actin Antibody Revenue by Country (2021-2032)
- 5.6.4 China
- 5.6.5 Japan
- 5.6.6 South Korea
- 5.6.7 India
- 5.6.8 Australia
- 5.6.9 Taiwan
- 5.6.10 Southeast Asia
- 5.7 South America Anti-Beta-Actin Antibody Market Facts & Figures by Country
- 5.7.1 South America Anti-Beta-Actin Antibody Market Size by Country: 2021 VS 2025 VS 2032
- 5.7.2 South America Anti-Beta-Actin Antibody Sales by Country (2021-2032)
- 5.7.3 South America Anti-Beta-Actin Antibody Revenue by Country (2021-2032)
- 5.7.4 Brazil
- 5.7.5 Argentina
- 5.7.6 Chile
- 5.8 Middle East and Africa Anti-Beta-Actin Antibody Market Facts & Figures by Country
- 5.8.1 Middle East and Africa Anti-Beta-Actin Antibody Market Size by Country: 2021 VS 2025 VS 2032
- 5.8.2 Middle East and Africa Anti-Beta-Actin Antibody Sales by Country (2021-2032)
- 5.8.3 Middle East and Africa Anti-Beta-Actin Antibody Revenue by Country (2021-2032)
- 5.8.4 Egypt
- 5.8.5 South Africa
- 5.8.6 Israel
- 5.8.7 Türkiye
- 5.8.8 GCC Countries
6 Segment by Type
- 6.1 Global Anti-Beta-Actin Antibody Sales by Type (2021-2032)
- 6.1.1 Global Anti-Beta-Actin Antibody Sales by Type (2021-2032) & (ml)
- 6.1.2 Global Anti-Beta-Actin Antibody Sales Market Share by Type (2021-2032)
- 6.2 Global Anti-Beta-Actin Antibody Revenue by Type (2021-2032)
- 6.2.1 Global Anti-Beta-Actin Antibody Sales by Type (2021-2032) & (US$ Million)
- 6.2.2 Global Anti-Beta-Actin Antibody Revenue Market Share by Type (2021-2032)
- 6.3 Global Anti-Beta-Actin Antibody Price by Type (2021-2032)
7 Segment by Application
- 7.1 Global Anti-Beta-Actin Antibody Sales by Application (2021-2032)
- 7.1.1 Global Anti-Beta-Actin Antibody Sales by Application (2021-2032) & (ml)
- 7.1.2 Global Anti-Beta-Actin Antibody Sales Market Share by Application (2021-2032)
- 7.2 Global Anti-Beta-Actin Antibody Revenue by Application (2021-2032)
- 7.2.1 Global Anti-Beta-Actin Antibody Sales by Application (2021-2032) & (US$ Million)
- 7.2.2 Global Anti-Beta-Actin Antibody Revenue Market Share by Application (2021-2032)
- 7.3 Global Anti-Beta-Actin Antibody Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
- 8.1 Anti-Beta-Actin Antibody Value Chain Analysis
- 8.1.1 Anti-Beta-Actin Antibody Key Raw Materials
- 8.1.2 Raw Materials Key Suppliers
- 8.1.3 Anti-Beta-Actin Antibody Production Mode & Process
- 8.2 Anti-Beta-Actin Antibody Sales Channels Analysis
- 8.2.1 Direct Comparison with Distribution Share
- 8.2.2 Anti-Beta-Actin Antibody Distributors
- 8.2.3 Anti-Beta-Actin Antibody Customers
9 Global Anti-Beta-Actin Antibody Analyzing Market Dynamics
- 9.1 Anti-Beta-Actin Antibody Industry Trends
- 9.2 Anti-Beta-Actin Antibody Industry Drivers
- 9.3 Anti-Beta-Actin Antibody Industry Opportunities and Challenges
- 9.4 Anti-Beta-Actin Antibody Industry Restraints
10 Report Conclusion
11 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst